PMCB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
PharmaCyte Biotech Inc (PMCB) is not a strong buy for a beginner, long-term investor with $50,000-$100,000 available for investment. The technical indicators are mixed, options data shows minimal activity, financial performance is weak, and there are no significant positive catalysts or trading signals to support an immediate buy decision.
The MACD is positive and expanding, indicating slight bullish momentum. However, RSI is neutral at 58.448, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point (0.709), with resistance at 0.771 and support at 0.647. Overall, the technical setup does not strongly favor a buy.
NULL. No recent news, no significant insider or hedge fund activity, and no congress trading data.
Weak financial performance in Q3 2026, with a YoY net income drop of -48.90% and EPS decline of -61.36%. Stock trend analysis predicts a potential decline of -1.24% in the next week and -3.11% in the next month.
In Q3 2026, the company reported zero revenue growth (0.00% YoY), a net income drop to -1,556,255 (-48.90% YoY), and a significant EPS decline to -0.17 (-61.36% YoY). Gross margin remains at 0, indicating no profitability.
No analyst rating or price target data available.
